-
Entity
-
Individual
-
Location
-
C/O Atara Biotherapeutics, Inc., 3260 Bayshore Boulevard, Brisbane, California
-
Summary
-
The estimated net worth of Christopher Haqq is at least $197K dollars as of February 5, 2024. Christopher Haqq is the Title: Executive Vice President, Head of R&D and Chief Medical Officer of Elicio Therapeutics, Inc. and owns shares of Elicio Therapeutics, Inc. (ELTX) stock worth about $186K. Christopher Haqq is the Former Director of Surrozen, Inc./DE and owns shares of Surrozen, Inc./DE (SRZN) stock worth about $11.4K.